All notes

3 min readFundraising

Biotech pre-seed fundraising milestones

A practical way to connect biotech experiments, reproducibility, customer evidence and financing needs in a pre-seed or seed pitch.

By Variance Ventures

A biotech fundraising milestone should describe an uncertainty the company will resolve. “Hire two scientists” describes an input. “Determine whether the result can be reproduced under a defined protocol outside the founding lab” describes a question the financing can help answer.

For founders raising biotech pre-seed funding, that distinction makes the budget easier to understand. It also helps investors assess whether the proposed round can produce evidence relevant to the next financing or commercial decision.

Name the business before choosing the experiments

Different business models need different evidence. A research software company may need to show that scientists can complete a workflow using its product. A laboratory automation company may need reliability and throughput data. A therapeutic developer faces a development path that cannot be reduced to software adoption metrics.

Write one sentence identifying the initial product, its user or partner, and the decision your next evidence package should support. Then list the assumptions beneath it. Which assumption would most weaken the company’s plan if it turned out to be false?

That is a useful place to start planning the round. It does not mean every experiment should address the most ambitious long-term claim.

Separate prediction, measurement, and interpretation

Consider an illustrative computational protein design company. It can produce candidate designs, test selected candidates, and interpret what the measurements imply. Each step contains separate uncertainties.

For a pitch, describe how candidates are selected before testing, what comparison is meaningful, and which conditions the results cover. Explain the difference between an exploratory observation and a result tested again under a stable protocol. Report exclusions and unsuccessful experiments that materially affect interpretation.

The point is to make the learning process legible. A strong result on a narrow task can be useful without implying a general biological capability or a clinical benefit.

Turn a milestone into a decision rule

For each major milestone, write down five things:

  • The hypothesis being tested and why it matters commercially.
  • The evidence that would support continuing the current approach.
  • The result that would trigger another experiment, a redesign, or a change of direction.
  • The people, facilities, materials, and rights needed to run the work.
  • The cost and timeline, including the main sources of uncertainty.

The thresholds should come from the science and the intended application. An arbitrary headline metric may look precise while offering little help in deciding what to do next.

Budget the dependencies that can stop the work

Include more than salaries and consumables. Laboratory availability, equipment servicing, samples, external testing, data licenses, shipping, and institutional agreements may control the pace of progress.

For an academic spinout, explain the status of relevant intellectual property arrangements and access to facilities. For outsourced experiments, identify who receives the underlying records and whether the company can reproduce the work elsewhere. For proprietary datasets, explain access and use rights rather than relying on an informal relationship.

Show a base plan and a plausible delay case. If an experiment takes longer or a dependency becomes unavailable, what can the team still learn? A staged budget helps an investor understand the sequence without assuming that every part of the research proceeds as expected.

Add commercial learning where it belongs

Scientific progress and customer interest are complementary forms of evidence. They should remain distinguishable in the deck.

For a research tool, a prospective customer might help define an evaluation workflow. Explain the customer’s existing process, why the proposed change matters, and what would lead to a paid purchase. For a platform pursuing partnerships, describe the work needed before a partner can make a decision. A conversation, a letter of intent, and a funded agreement do not represent the same commitment.

Match the capital to the milestone

Once the plan is clear, build the round around the total cost and timing. Seek investors whose expertise and financing approach fit that plan. Our biotech investor guide distinguishes several options; our small-check guide explains the role of smaller participants.

Variance Ventures invests at seed and pre-seed, primarily in the US while considering founders globally. Typical initial checks are around $50,000, with flexibility. See our biotechnology focus and broader investment overview for context. If there is a fit, pitch us with the current evidence, the unresolved question, and the capital required to answer it.